J Korean Neuropsychiatr Assoc.  2019 Feb;58(1):55-63. 10.4306/jknpa.2019.58.1.55.

Reliability and Validity of the Korean Version of the Birchwood Insight Scale

• Jang JH
• Lee NY
• Kim YS
• Park SW

• KMID: 2439028
• DOI: http://doi.org/10.4306/jknpa.2019.58.1.55

Abstract

OBJECTIVES
In the treatment of schizophrenia, treatment compliance is an important prognostic factor. As insight has a significant impact on treatment compliance, an appropriate assessment of insight is essential in the treatment of schizophrenia. This study examined the reliability and validity of the Korean version of Birchwood Insight Scale (BIS).
METHODS
Fifty seven adult patients diagnosed with schizophrenia according to DSM-5 were recruited from a university hospital. They were evaluated using the Positive and Negative Syndrome Scale (PANSS), The Scale to Assessment Unawareness of Mental Disorder (SUMD) and BIS. Explorative factor analysis was performed to examine the construct validity of the Korean version of BIS. Concurrent validity was evaluated by a comparison with the PANSS G12 item and SUMD. The test-retest correlation was evaluated to examine the test-retest reliability. Multiple regression analysis was performed to examine the variables affecting insight.
RESULTS
Explorative factor analysis showed that the Korean version of BIS was composed of 2 factors, which are "˜Awareness of symptoms' and "˜Awareness of illness and need for treatment.' The Korean version of BIS was reliable in terms of the internal consistency. Concurrent validity with the PANSS G 12 item and SUMD was statistically significant. The test-retest reliability was also statistically significant. Multiple regression analysis showed that the PANSS negative factor affects the BIS score, indicating that negative symptoms of schizophrenia may impair insight of the illness.
CONCLUSION
This study suggests that the Korean version of BIS is a valid and reliable tool for assessing the insight of patients with schizophrenia.

Keyword

Schizophrenia; Insight; Psychopathology; Negative symptom; Self-Rating Scale

MeSH Terms

Adult
Compliance
Humans
Mental Disorders
Psychopathology
Reproducibility of Results*
Schizophrenia

Reference

1. Cleary SD, Bhatty S, Broussard B, Cristofaro SL, Wan CR, Compton MT. Measuring insight through patient self-report: an in-depth analysis of the factor structure of the Birchwood Insight Scale. Psychiatry Res. 2014; 216:263–268.

2. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. Am J Psychiatry. 1993; 150:873–879.

3. Monteiro LC, Silva VA, Louzã MR. Insight, cognitive dysfunction and symptomatology in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2008; 258:402–405.

4. Brent BK, Giuliano AJ, Zimmet SV, Keshavan MS, Seidman LJ. Insight into illness in patients and caregivers during early psychosis: a pilot study. Schizophr Res. 2011; 127:100–106.

5. Garavan J, Browne S, Gervin M, Lane A, Larkin C, O'callaghan E. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry. 1998; 39:215–219.

6. Rüsch N, Corrigan PW. Motivational interviewing to improve insight and treatment adherence in schizophrenia. Psychiatr Rehabil J. 2002; 26:23–32.

7. Lysaker PH, Dimaggio G, Buck KD, Callaway SS, Salvatore G, Carcione A, et al. Poor insight in schizophrenia: links between different forms of metacognition with awareness of symptoms, treatment need, and consequences of illness. Compr Psychiatry. 2011; 52:253–260.

8. Hillis JD, Leonhardt BL, Vohs JL, Buck KD, Salvatore G, Popolo R, et al. Metacognitive reflective and insight therapy for people in early phase of a schizophrenia spectrum disorder. J Clin Psychol. 2015; 71:125–135.

9. Aleman A, Agrawal N, Morgan KD, David AS. Insight in psychosis and neuropsychological function. Br J Psychiatry. 2006; 189:204–212.

10. Burton CZ, Twamley EW. Neurocognitive insight, treatment utilization, and cognitive training outcomes in schizophrenia. Schizophr Res. 2015; 161:399–402.

11. Fervaha G, Foussias G, Agid O, Remington G. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr Scand. 2014; 130:290–299.

12. Shad MU, Muddasani S, Prasad K, Sweeney JA, Keshavan MS. Insight and prefrontal cortex in first-episode schizophrenia. Neuroimage. 2004; 22:1315–1320.

13. Sapara A, Cooke M, Fannon D, Francis A, Buchanan RW, Anilkumar AP, et al. Prefrontal cortex and insight in schizophrenia: a volumetric MRI study. Schizophr Res. 2007; 89:22–34.

14. Ha TH, Youn T, Ha KS, Rho KS, Lee JM, Kim IY, et al. Gray matter abnormalities in paranoid schizophrenia and their clinical correlations. Psychiatry Res. 2004; 132:251–260.

15. Sapara A, Ffytche DH, Cooke MA, Williams SC, Kumari V. Voxelbased magnetic resonance imaging investigation of poor and preserved clinical insight in people with schizophrenia. World J Psychiatry. 2016; 6:311–321.

16. Drake RJ, Lewis SW. Insight and neurocognition in schizophrenia. Schizophr Res. 2003; 62:165–173.

17. Morgan KD, Dazzan P, Morgan C, Lappin J, Hutchinson G, Suckling J, et al. Insight, grey matter and cognitive function in first-onset psychosis. Br J Psychiatry. 2010; 197:141–148.

18. Liemburg EJ, Van der Meer L, Swart M, Curcic-Blake B, Bruggeman R, Knegtering H, et al. Reduced connectivity in the self-processing network of schizophrenia patients with poor insight. PLoS One. 2012; 7:e42707.

19. Spalletta G, Piras F, Piras F, Caltagirone C, Orfei MD. The structural neuroanatomy of metacognitive insight in schizophrenia and it psychopathological and neuropsychological correlates. Hum Brain Mapp. 2014; 35:4729–4740.

20. Nair A, Palmer EC, Aleman A, David AS. Relationship between cognition, clinical and cognitive insight in psychotic disorders: a review and meta-analysis. Schizophr Res. 2014; 152:191–200.

21. Shad MU, Keshavan MS. Neurobiology of insight deficits in schizophrenia: an fMRI study. Schizophr Res. 2015; 165:220–226.

22. Lin IF, Spiga R, Fortsch W. Insight and adherence to medication in chronic schizophrenics. J Clin Psychiatry. 1979; 40:430–432.

23. Amador XF, Strauss DH, Yale SA, Gorman JM. Awareness of illness in schizophrenia. Schizophr Bull. 1991; 17:113–132.

24. David AS. Insight and psychosis. Br J Psychiatry. 1990; 156:798–808.

25. Saravanan B, Jacob KS, Prince M, Bhugra D, David AS. Culture and insight revisited. Br J Psychiatry. 2004; 184:107–109.

26. Jacob KS. Insight in psychosis: standards, science, ethics and value judgment. Int J Soc Psychiatry. 2017; 63:345–351.

27. McCabe R, Priebe S. The therapeutic relationship in the treatment of severe mental illness: a review of methods and findings. Int J Soc Psychiatry. 2004; 50:115–128.

28. Saravanan B, Jacob KS, Johnson S, Prince M, Bhugra D, David AS. Outcome of first-episode schizophrenia in India: longitudinal study of effect of insight and psychopathology. Br J Psychiatry. 2010; 196:454–459.

29. McEVOY JP, Apperson LJ, Appelbaum PS, Ortlip P, Brecosky J, Hammill K, et al. Insight in schizophrenia. Its relationship to acute psychopathology. J Nerv Ment Dis. 1989; 177:43–47.

30. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report insight scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand. 1994; 89:62–67.

31. Marks KA, Fastenau PS, Lysaker PH, Bond GR. Self-Appraisal of Illness Questionnaire (SAIQ): relationship to researcher-rated insight and neuropsychological function in schizophrenia. Schizophr Res. 2000; 45:203–211.

32. Marková IS, Berrios GE. The assessment of insight in clinical psychiatry: a new scale. Acta Psychiatr Scand. 1992; 86:159–164.

33. Jovanovski D, Zakzanis KK, Atia M, Campbell Z, Young DA. A comparison between a researcher-rated and a self-report method of insight assessment in chronic schizophrenia revisited: a replication study using the SUMD and SAIQ. J Nerv Ment Dis. 2007; 195:165–169.

34. Karow A, Pajonk FG, Reimer J, Hirdes F, Osterwald C, Naber D, et al. The dilemma of insight into illness in schizophrenia: self-and expertrated insight and quality of life. Eur Arch Psychiatry Clin Neurosci. 2008; 258:152–159.

35. Jeong SH, Chung IW, Jung HY, Hwang SS, Kim SH, Youn T, et al. Comparison of clinician-rated and self-report insight in Korean patients with schizophrenia using VAGUS insight scale. Psychiatry Res. 2017; 258:93–100.

36. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). 5th ed. Washington DC: American Psychiatric Association;2013.

37. Roncone R, Tozzini C, Mazza M, De Risio A, Giosuè P, Morosini P, et al. [Validation of the Italian version of the self-report insight scale]. Epidemiol Psichiatr Soc. 2003; 12:63–75.

38. Song JY, Kim KT, Lee SK, Kim YH, Noh JH, Kim JW, et al. Reliability and validity of the Korean version of the scale to assessment unawareness of mental disorder (SUMD-K). J Korean Neuropsychiatr Assoc. 2006; 45:307–315.

39. Michel P, Baumstarck K, Auquier P, Amador X, Dumas R, Fernandez J, et al. Psychometric properties of the abbreviated version of the scale to assess unawareness in mental disorder in schizophrenia. BMC Psychiatry. 2013; 13:229.

40. Kay SR, Fiszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13:261–276.

41. Yi JS, Ahn YM, Shin HK, An SK, Joo YH, Kim SH, et al. Reliability and validity of the Korean version of the positive and negative syndrome scale. J Korean Neuropsychiatr Assoc. 2001; 40:1090–1105.

42. Hwang SS, Chang JS, Lee KY, Ahn YM, Kim YS. The causal model of insight in schizophrenia based on the positive and negative syndrome scale factors and the structural equation modeling. J Nerv Ment Dis. 2009; 197:79–84.

43. Gilleen J, Greenwood K, David AS. Domains of awareness in schizophrenia. Schizophr Bull. 2010; 37:61–72.

44. Gerretsen P, Remington G, Borlido C, Quilty L, Hassan S, Polsinelli G, et al. The VAGUS insight into psychosis scale–self-report and clinician-rated versions. Psychiatry Res. 2014; 220:1084–1089.

45. Huang M, Huang Y, Yu L, Hu J, Chen J, Jin P, et al. Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia. BMC Psychiatry. 2016; 16:344.

46. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004; 68:1–9.

47. MacBeth A, Gumley A, Schwannauer M, Carcione A, Fisher R, McLeod HJ, et al. Metacognition, symptoms and premorbid functioning in a first episode psychosis sample. Compr Psychiatry. 2014; 55:268–273.

48. Hutcheson GD, Sofroniou N. The multivariate social scientist: introductory statistics using generalized linear models. LA: Sage Publications;1999.